UCB Wins Two Key US Approvals: Bimzelx In Psoriasis, Zilbrysq In gMG
Launches To Follow In A Month, Late 2023
Executive Summary
Two years after its first FDA review, UCB’s next blockbuster Bimzelx finally crossed the finish line. Supplemental filings for more indications will soon follow as the company forecasts €4bn in peak sales.